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Aging and age-related diseases, such as diabetes, atherosclerosis, and neurodegenerative diseases, are characterized by
increases in oxidative chemical modification of tissue proteins
(1, 2). Some oxidation products, e.g. methionine sulfoxide and
o-tyrosine, are formed by direct oxidation of amino acids in
proteins. Glycoxidation products or advanced glycoxidation end
products (AGEs),1 such as the cross-links pentosidine and ves* This work was supported by NIDDKD Research Grant DK-19971
from the National Institutes of Health. The costs of publication of this
article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom all correspondence should be addressed: Dept. of Chemistry and Biochemistry, University of South Carolina, Columbia SC
29208. Tel.: 803-777-7272; Fax: 803-777-7272; E-mail: baynes@
mail.chem.sc.edu.
1
The abbreviations used are: AGE, advanced glycation end product;
AA, arachidonic acid; CEL, N⑀-(carboxyethyl)lysine; CML, N⑀-(carboxymethyl)lysine; DTPA, diethylenetriaminepentaacetic acid; HNELys, Michael addition adduct of lysine to 4-hydroxynonenal; KODE,
keto-octadecadienoic acid (9-oxo-11,13-octadecadienoic acid or 13-oxoThis paper is available on line at http://www.jbc.org

perlysines (3, 4), are produced by secondary modification of
proteins by products of carbohydrate oxidation. Advanced lipoxidation end products (ALEs), including malondialdehyde
(MDA) and hydroxynonenal (HNE) adducts to lysine (MDALys, HNE-Lys) (5) and pyrroles (6), are formed during lipid
peroxidation reactions, whereas other compounds, such as N⑀(carboxymethyl)lysine (CML) and N⑀-(carboxyethyl)lysine
(CEL), are formed during both glycoxidation and lipoxidation
reactions (7). Age-adjusted levels of pentosidine and CML are
increased during chronic hyperglycemia and correlate with the
severity of renal, retinal, and vascular complications in diabetes (8). Inhibitors of AGE formation, such as aminoguanidine
(9), tenilsetam (10), OPB-9195 (11), and pyridoxamine (PM)
(12, 13), also retard the development of diabetic complications
in animal models, and aminoguanidine and PM are being evaluated in clinical trials for treatment of diabetic nephropathy.
Although AGE inhibitors vary widely in structure, they are all
nucleophilic compounds and are thought to function by trapping reactive carbonyl intermediates in AGE formation. Because they are relatively nonspecific nucleophiles, AGE inhibitors also affect other oxidative chemistry, e.g. the formation of
ALEs. Aminoguanidine, for example, inhibits chemical modification of proteins during lipid peroxidation reactions (14) and
inhibits metal-catalyzed oxidation of low density lipoprotein
(LDL) and uptake of oxidized LDL into macrophages via the
scavenger receptor (15).
The AGE inhibitor PM was introduced by Hudson and colleagues (12, 13) as an inhibitor of AGE formation from Amadori
compounds, the first stable sugar-protein adducts formed during glycation of protein. In animal model studies, PM also
inhibited AGE formation and retarded the development of nephropathy in streptozotocin-induced diabetic rats.2,3 However,
the renal protection was accompanied by a significant reduction in hypertriglyceridemia, and there were strong correlations between plasma triglyceride concentration and the levels
of CML and CEL, fluorescence, and cross-links in skin collagen.
These observations suggested that, in addition to its AGEinhibitory activity, PM might also affect lipid homeostasis and
9,11-octadecadienoic acid); LA, linoleic acid; LC-ESI-MS, liquid chromatography-electrospray ionization-mass spectrometry; LDL, low density lipoprotein; MDA, malondialdehyde; MDA-Lys, malondialdehydelysine, Schiff base adduct; PM, pyridoxamine; PUFA, polyunsaturated
fatty acid; RNase, bovine pancreatic ribonuclease A; RP-HPLC, reversephase high performance liquid chromatography; TBARs, thiobarbituric
acid-reactive substances; TNBS, trinitrobenzenesulfonic acid; MS,
mass spectrometry; GC/MS, gas chromatography/mass spectrometry;
ALEs, advanced lipoxidation end products.
2
T. P. Degenhardt, N. L. Alderson, D. D. Arrington, R. J. Beattie,
S. R. Thorpe, and J. W. Baynes, submitted for publication.
3
T. P. Degenhardt, N. L. Alderson, R. J. Beattie, J. M. Basgen, M. W.
Steffes, S. R. Thorpe, and J. W. Baynes, submitted for publication.
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Maillard or browning reactions lead to formation of
advanced glycation end products (AGEs) on protein and
contribute to the increase in chemical modification of
proteins during aging and in diabetes. AGE inhibitors
such as aminoguanidine and pyridoxamine (PM) have
proven effective in animal model and clinical studies as
inhibitors of AGE formation and development of diabetic complications. We report here that PM also inhibits the chemical modification of proteins during lipid
peroxidation (lipoxidation) reactions in vitro, and we
show that it traps reactive intermediates formed during
lipid peroxidation. In reactions of arachidonate with the
model protein RNase, PM prevented modification of lysine residues and formation of the advanced lipoxidation end products (ALEs) N⑀-(carboxymethyl)lysine, N⑀(carboxyethyl)lysine,
malondialdehyde-lysine,
and
4-hydroxynonenal-lysine. PM also inhibited lysine modification and formation of ALEs during copper-catalyzed oxidation of low density lipoprotein. Hexanoic
acid amide and nonanedioic acid monoamide derivatives of PM were identified as major products formed
during oxidation of linoleic acid in the presence of PM.
We propose a mechanism for formation of these products from the 9- and 13-oxo-decadienoic acid intermediates formed during peroxidation of linoleic acid. PM, as
a potent inhibitor of both AGE and ALE formation, may
prove useful for limiting the increased chemical modification of tissue proteins and associated pathology in
aging and chronic diseases, including both diabetes and
atherosclerosis.
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lipid-dependent chemical modification of protein in vivo. In this
paper we describe experiments in vitro on the effects of PM on
the chemical modification of proteins during lipid peroxidation
reactions, and we show that PM is a potent inhibitor of modification of lysine by peroxidizing lipids, both in a model proteinlipid system and during copper-catalyzed oxidation of LDL. We
also identify the major products formed on reaction of linoleic
acid (LA) with PM under autoxidative conditions, the hexanoic
acid amide and nonanedioic acid monoamide derivatives of PM,
and we propose a mechanism for PM inhibition of chemical
modification of proteins during lipoxidation reactions. Our results provide insight into the mechanism of action of PM as an
AGE and ALE inhibitor, and we suggest that PM may be useful
for inhibiting the increased chemical modification of tissue
proteins, whether derived from carbohydrate or lipids, in diabetes, atherosclerosis, and other chronic diseases.
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MATERIALS AND METHODS

Chemicals—Arachidonic acid (AA), LA, oleic acid, palmitic acid,
PM䡠(HCl)2, pyridoxal䡠(HCl), pyridoxine䡠(HCl), ribonuclease A (type II-A
from bovine pancreas; RNase), diethylenetriaminepentaacetic acid
(DTPA), phytic acid, butylated hydroxytoluene, NaBH4, hexanoyl (caproyl) chloride, methyl linoleate, and nonanedioic (azelaic) acid monomethyl ester were purchased from Sigma. Boron trichloride-methanol
was purchased from Pierce and heptafluorobutyric acid from Acros
Chemicals (Atlanta, GA). [ 2 H 4 ]- and [ 2 H 8 ]lysine were from
Isotec (Miamisburg, OH). Deuterated and natural abundance internal
standards (CML and [2H4]CML, CEL and [2H4]CEL, MDA-Lys and
[2H8]MDA-Lys, and HNE-Lys and [2H4]HNE-Lys) were prepared as
described previously (5, 18, 19).
Reaction of PM with Fatty Acids—PM (1 mM) was incubated with AA,
LA, or oleic acid (5 mM) in 5 ml of filter-sterilized 200 mM sodium
phosphate buffer, pH 7.4, in 20-ml scintillation vials for 6 days at 37 °C
in a shaking water bath. Reactions were initially biphasic but, in the
case of the polyunsaturated fatty acids (PUFA) AA and LA, became
monophasic by day 3. Aliquots were removed from the aqueous phase
and stored at ⫺20 °C until analyzed. Modification of the free amino
group of PM was measured by the trinitrobenzenesulfonic acid (TNBS)
assay (20), using PM as standard. Reversed-phase high performance
liquid chromatographic analysis of the samples was carried out on a
Waters (Milford, MA) HPLC system, using a Supelco (Bellefonte, PA)
C-18 column (4.6 mm ⫻ 25 cm). The gradient (flow rate ⫽ 1 ml/min;
solvent A ⫽ 0.1% aqueous heptafluorobutyric acid and solvent B ⫽
acetonitrile) was as follows: 0 –2 min, 100% A; 2–20 min, linear gradient
to 60% B; hold 10 min; 30 –31 min, linear gradient to 75% B; hold 10
min; 41– 42 min, linear gradient to 100% A, hold 13 min to re-equilibrate column. PM and derivatives were detected by fluorescence at Ex ⫽
328 nm and Em ⫽ 393 nm and were quantified by absorbance detection
at 294 nm.
Effect of PM on Oxidation of LA—LA (5 mM) was oxidized alone or in
the presence of PM (1 mM), as described above. Individual reaction
vessels were removed at various times (0, 1, 3, and 6 days); DTPA was
added (final concentration ⫽ 1 mM from 100 mM stock), and the samples
were then stored at ⫺20 °C until analyzed. Aliquots of well mixed
reaction mixtures were removed for measurement of thiobarbituric acid
reacting substances (TBARs), as described by Sawicki et al. (21), using
MDA as external standard. For measurement of residual LA, butylated
hydroxytoluene (antioxidant, 0.01%) and palmitate (internal standard,
5 mM) were added, and then the lipids were extracted with CHCl3:
CH3OH (2:1), as described by Folch et al. (22), and the organic layer was
dried in vacuo. Linoleate was converted to methyl linoleate using 0.5 ml
of boron trichloride:methanol heated at 65 °C for 1 h. The derivatizing
agent was evaporated under nitrogen, and the methyl esters were
extracted with hexane:water (3:1, v/v). The organic layer was dried
under nitrogen, reconstituted in 0.15 ml of CH2Cl2, and analyzed by
selected ion monitoring-gas chromatography/mass spectrometry (SIMGC/MS) (see below) using ions 294 and 220 for methyl linoleate and
methyl palmitate, respectively.
Reaction of RNase with AA—RNase (1 mM, 13.7 mg/ml; equivalent to
10 mM lysine concentration) was reacted with AA (100 mM) in the
absence or presence of PM (1 mM) in 5 ml of 0.2 M sodium phosphate
buffer, pH 7.4. The reactions were prepared under sterile conditions,
using ultrafiltered solutions. Aliquots were removed at 0, 1, 3, and 6
days, DTPA was added (final concentration ⫽ 1 mM), and the samples
were frozen at ⫺20 °C. Aliquots (⬃1 mg of protein) were extracted with

CHCl3:CH3OH, according to Folch (22), and the lower organic phase
was removed. The upper aqueous phase and interfacial protein were
reduced by addition of a 5-fold excess of NaBH4 over lipid in 0.1 M borate
buffer, pH 9, for 4 h at room temperature. The samples were then
transferred to dialysis tubing (6,000 – 8,000 molecular weight cut-off)
and dialyzed against 100 volumes of deionized water for 24 h at 4 °C
with several water changes. An aliquot of the dialysate, equivalent to
⬃100 g of protein, was removed, diluted with an equal volume of
concentrated HCl, and hydrolyzed (110 °C for 24 h) for amino acid
analysis. Modification of lysine residues was measured by amino acid
analysis, conducted by cation-exchange chromatography, using postcolumn derivatization with o-phthalaldehyde and fluorescence detection. For analysis of lipoxidation products, the remainder of the sample
was dried in vacuo, deuterated internal standards ([2H8]Lys, [2H4]CML,
[2H4]CEL, [2H8]MDA-Lys, and [2H4]HNE-Lys) were added, and the
sample was hydrolyzed in 6 N HCl, as above. The hydrolysate was dried
in vacuo, reconstituted in 1 ml of 0.1% trifluoroacetic acid, and applied
to a 1-ml C-18 Sep-Pak (Waters Associates, Milford, MA) equilibrated
with 0.1% trifluoroacetic acid. The flow-through fraction from the column was collected, and the column was washed with 3 ml of 0.1%
trifluoroacetic acid containing 20% methanol. The eluate was pooled
with the flow-through fraction, dried in vacuo, and the amino acids then
derivatized as their N,O-trifluoroacetyl methyl esters and analyzed by
selected ion monitoring (SIM)-GC/MS, as described previously (5, 18,
19).
Oxidation of LDL—LDL was isolated from plasma of healthy donors
by single-vertical spin centrifugation and used within 24 – 48 h of preparation, as described previously (18). LDL (50 g of protein/ml) was
incubated at 37 °C in phosphate-buffered saline alone or in the presence
of 5 M CuCl2 or 5 M CuCl2 plus PM (100 –250 M). Formation of
conjugated dienes, an index of lipid peroxidation, was monitored at 234
nm. Aliquots corresponding to ⬃1 mg of LDL protein were removed at
various times, reduced with NaBH4, and hydrolyzed for amino acid
analysis and measurement of ALEs, as described previously (18).
Other Methods—N-Hexanoyl-pyridoxamine was synthesized from
PM䡠(HCl)2 and hexanoyl chloride. PM (20 mg) was dissolved in 50 ml of
2 M NaOH in a 250-ml round bottom flask. Hexanoyl chloride (22 mg in
30 ml of dry ether) was added dropwise over an hour while the reaction
was kept on ice and stirred vigorously. The reaction was stirred for an
additional 2 h and then the ether layer was removed and dried under
nitrogen, yielding a white powder. N-Hexanoyl-PM was identified and
isolated by RP-HPLC with detection by absorbance and electrospray
ionization/mass spectrometry (ESI-LC/MS), as described below.
N-Nonanedioyl-pyridoxamine was synthesized according to D’Alelio
and Reid (23). Briefly, 0.3 g of PM in 0.3 ml of deionized water was
added to 0.3 g of azelaic acid monomethyl ester and heated at 140 °C for
10 h. The brown reaction mixture was dried in vacuo and reconstituted
in deionized water:acetonitrile (1:1, v/v). N-Nonanedioyl-PM was identified and isolated by RP-HPLC with detection by absorbance and
ESI-LC/MS, as described below.
N-Acyl-PM derivatives were hydrolyzed in 2 M HCl for 4 h at 95 °C,
releasing free PM and carboxylic acids. The hydrolysate was dried in
vacuo, and the resulting free carboxylic acids (hexanoic and nonanedioic
acids) were analyzed by GC/MS as their propyl and dimethyl esters,
respectively. Esterification was performed in 1 ml of 1 M HCl in n-propyl
alcohol or methanol at 65 °C for 1 h. After drying in vacuo, the esters
were extracted into 2 ml of hexane:water (2:1, v/v). Following vortexing
and centrifugation, the hexane phase was analyzed by GC/MS, as
described below. The aqueous phase, containing PM, was dried in
vacuo, and the PM was acetylated by reaction with acetic anhydride:
pyridine (1:1, v/v) for 2 h at room temperature. Following evaporation in
vacuo, the product was reconstituted in methylene chloride for GC/MS
analysis.
Mass Spectrometry—ESI-LC-MS was carried out in the positive ion
mode on a VG (Manchester, UK) Trio-3 triple quadrupole mass spectrometer equipped with a Hewlett-Packard (Palo Alto, CA) series 1100
HPLC system and a Keystone (Bellefonte, PA) Aquasil C-18 microbore
column. The solvent system consisted of 0.1% heptafluorobutyric acid
(solvent A) and acetonitrile (solvent B), flow rate 0.05 ml/min. The
gradient used was as follows: 100% A, hold for 2 min; 6 min ramp to 60%
B, hold for 4 min; 3 min ramp to 75% B, hold for 10 min. GC/MS was
carried out on a Hewlett-Packard model 6890 gas chromatograph/5970
mass selective detector, using a 30-meter HP-5MS (5% phenyl methyl
siloxane) capillary column (Restek, Bellefonte, PA). The temperature
program for analyses of PM and carboxylic acid esters was as follows:
initial temperature 75 °C, 6 °C/min ramp to 110 °C, 10 °C/min ramp to
180 °C hold 5 min, 12 °C/min ramp to 270 °C/min, hold 5 min. Fast atom
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bombardment-MS was performed on a VG (Manchester, UK) 70 SQ
high resolution, magnetic sector mass spectrometer.
RESULTS

Reaction of PM with PUFAs—To study the interaction of PM
with products of lipid peroxidation, PM was incubated with
oleate or PUFA in phosphate buffer at physiological pH, relying
on endogenous metal ions in the phosphate buffer to catalyze
PUFA oxidation. As shown in Fig. 1A, PM incubated alone or in
the presence of oleate was recovered unchanged over the 6-day
incubation period. However, in the presence of LA and AA, PM
was gradually consumed, with ⬃60% PM loss at 6 days, based
on HPLC analysis (see inset to Fig. 4). When the same samples
were analyzed by the TNBS assay (Fig. 1B), ⬃60% of the free
amino groups of PM was also modified during peroxidation of
PUFA. The close agreement between the loss of PM by HPLC
and the loss of amino groups by the TNBS reaction suggested
that PM was reacting with products of lipid peroxidation via its
benzylic amino group. PUFA were also solubilized at similar
rates in the presence and absence of PM, and as shown in
Fig. 2, the kinetics of formation and yield of TBARs and the
rate of loss of LA, the primary PUFA in LDL (see below), were
only slightly affected by the presence of PM in reaction mixtures at 1 mM concentration. These experiments indicate that
PM, at the concentration used (1 mM) in the above experiment,
did not prevent lipid peroxidation by chelation or antioxidant
activity.
PM Inhibition of Lipoxidative Modification of RNase by AA—
The activity of PM as an inhibitor of lipoxidative modification
of proteins was studied in reactions of AA with RNase. As
shown in Fig. 3, CML, CEL, MDA-Lys, and HNE-Lys were
formed continuously on RNase during the incubation with AA.

FIG. 2. Pyridoxamine has minimal effect on the kinetics of
oxidation of linoleate. Linoleate (5 mM) was incubated alone (Œ) or in
the presence of PM (1 mM) (⌬) in 200 mM sodium phosphate buffer, pH
7.4, for 6 days at 37 °C. Aliquots removed at various times were analyzed for reactivity in the TBAR assay expressed as nmol MDA equivalents (A) and residual linoleate by GC/MS (B). Data are means ⫾ S.D.
of three independent experiments.

These studies confirm previous reports on the formation of
CML during lipid peroxidation reactions (18) and also identify
CEL as a product of arachidonate oxidation. The decline in
MDA-Lys recovered after 1 day resembles that observed during
copper oxidation of LDL and is thought to result from further
reaction of MDA-Lys to form other products, such as Lys-MDALys (5). Addition of 1 mM PM to the AA ⫹ RNase mixture
resulted in almost complete inhibition of formation of all the
ALEs. Notably, PM provided potent protection against lipoxidative modification of RNase, although it was present at only
1% the concentration of AA, and 10% the concentration of
lysine residues in RNase. The small increase in formation of
lipoxidation products by day 6 likely reflects the fact that all of
the PM had been consumed by that time, as shown in Fig. 4.
Amino acid analysis indicated that there was a progressive loss
of lysine during the reaction, with about 58% of lysine residues
lost at the end of 6 days in the absence of PM (Fig. 5). In
contrast, inclusion of PM in the incubation resulted in loss of
only about 5% of lysine residues by day 6.
Inhibition of LDL Oxidation by PM—Because PM inhibited
lipoxidation product formation in the AA ⫹ RNase system, we
also evaluated its effectiveness as an inhibitor of lipoxidation
during copper-catalyzed oxidation of LDL, a common in vitro
model for studies on lipoxidative modification of proteins. PM
was used at concentrations of 100 and 250 M concentrations,
comparable to the ⬃120 M concentration achieved in rats
treated with 1 g/liter in drinking water.2,3 At these concentrations, PM caused a 2–3-fold increase in the lag phase of LDL
oxidation and an ⬃20% decrease in absorbance at 234 nm
during the later plateau phase of the reaction (Fig. 6A). Confirming the results of experiments with AA and RNase, PM was
an effective inhibitor of formation of CML, CEL, MDA-Lys, and
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FIG. 1. Pyridoxamine is consumed during peroxidation of
fatty acids. PM (1 mM) was incubated alone (ƒ) or with oleate (E),
linoleate (⌬), or arachidonate (䡺) (5 mM) in 200 mM sodium phosphate
buffer, pH 7.4, for 6 days at 37 °C. A, loss of PM was quantified by
HPLC (see inset to Fig. 4). B, loss of primary amino groups, measured
by the TNBS assay. Data are means ⫾ S.D. of three independent
experiments.
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FIG. 4. Pyridoxamine is consumed during inhibition of chemical modification of RNase by arachidonate. RNase was incubated
with arachidonate and PM (1 mM) as described in the legend to Fig. 3.
Aliquots were removed at various times and assayed for residual PM by
HPLC (inset). Pyridoxal (PL) was added as an internal standard. Data
are means ⫾ S.D. of three independent experiments.

HNE-Lys (Fig. 6B.) during metal-catalyzed oxidation of LDL.
The relative yields of the ALEs during oxidation of LDL differed significantly from yields obtained in reactions of AA with
RNase, probably reflecting the heterogeneous fatty acid composition of LDL. PM was more effective in limiting formation of
CML and CEL, compared with MDA-Lys and HNE-Lys
(Fig. 6B), but was a potent inhibitor of the overall modification
of lysine residues in oxidized LDL (Fig. 6C), with only 6% loss
in the presence of PM compared with 29% in its absence.
Identification of PM Adducts—To identify products trapped
by PM during PUFA oxidation, we studied the reaction of PM
(1 mM) with LA, the primary PUFA in LDL. HPLC analyses of
the LA ⫹ PM reaction, described in Fig. 7, indicated formation

of products with fluorescence (Fig. 7, B versus A) and absorbance (Fig. 7C) maxima characteristic of PM. The consumption
of PM over a period of 6 days of reaction is evident, as well as
the time-dependent formation of new products eluting later
than PM, indicating that these adducts were more hydrophobic
than PM itself. Two major fluorescent products were consistently observed, eluting at ⬃24 min. Based on their fluorescence intensity, these two products accounted for ⱕ10% of the
PM in the starting reaction, whereas ⬃65% of the starting PM
was consumed by 6 days (Fig. 1). The fluorescence of the total
reaction mixture was also measured at 6 days, to establish that
fluorescent reaction products were not binding irreversibly to
the C-18 column. These measurements confirmed a significant
⬃50% decrease in fluorescence during the reaction, consistent
with the overall loss of fluorescence observed in the HPLC
analyses in Fig. 7C. This observation suggested that the PM
derivatives were less fluorescent than PM itself.
Semi-preparative RP-HPLC analysis (Fig. 7C) showed that a
number of additional products with absorbance maxima at 294
nm were also detected after 6 days of reaction. Those eluting
after about 23 min (indicated by an asterisk) had absorbance
maxima below 260 nm and were also formed from LA, in the
absence of PM. However, products eluting between 19 and 22
min had extracted absorbance maxima at 294 nm (photodiode
array detector), consistent with the presence of the intact pyridine ring. The peaks eluting in this region of the chromatogram were pooled and subjected to direct injection ESI-MS.
Major products identified had m/z values of 267, 305, 339, 377,
and 479 (Fig. 8A); none of these were present in incubations of
LA or PM alone. Assignment of the various species to particular chromatographic peaks was accomplished by collecting individual peaks by semi-preparative RP-HPLC (Fig. 8B) and
analysis by direct injection ESI-MS. Once peak assignments
were made, the kinetics of formation of the three most abundant products (267, 305, and 339) were determined by RPHPLC (Fig. 8C). The yields of all three compounds increased
with time, with products 267 and 339 consistently forming in
the highest yields. These products were chosen for further
characterization.
Product Characterization—Products 267 and 339 were identified as the hexanoic acid amide and nonanedioic (azelaic) acid
monoamide derivatives of PM (24). The hexanoic acid amide
derivative of lysine has been identified previously by Kato et al.
(25, 26) in reactions of linoleic acid hydroperoxides with N␣-
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FIG. 3. Pyridoxamine inhibits formation of ALEs during peroxidation of arachidonate in the presence of RNase. RNase (1
mM) was incubated with arachidonate alone (f) (100 mM) or in the
presence of PM (䡺) (1 mM) in 200 mM phosphate buffer, pH 7.4, for 6
days at 37 °C. By 3 days of incubation, all of the arachidonate had been
solubilized, yielding a monophasic system. At various times, aliquots of
the reaction were reduced with NaBH4, then dialyzed and prepared for
GC/MS as described under “Materials and Methods.” Approximately 1
mg of protein was analyzed by selected ion monitoring (SIM)-GC/MS for
CML (A), CEL (B), MDA-Lys (C), or HNE-Lys (D). Data are means ⫾
S.D. of three independent experiments.

FIG. 5. Pyridoxamine inhibits lysine modification during oxidation of arachidonate in the presence of RNase. Aliquots of the
reaction mixture described in the legend to Fig. 3 were analyzed by
amino acid analysis for their lysine content; data are expressed relative
to lysine content of native RNase. Data are means ⫾ S.D. of three
independent experiments.
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FIG. 7. Pyridoxamine is consumed, and fluorescent and absorbant products are formed during oxidation of linoleic acid. PM
(1 mM) was incubated with LA (5 mM) in 0.2 M sodium phosphate buffer,
pH 7.4, for 6 days at 37 °C. A and B, aliquots of the aqueous phase were
analyzed by analytical RP-HPLC at various times using fluorescence
detection with pyridoxal added as an internal standard, just prior to
chromatography. Products indicated by brackets were consistently
formed in reaction mixtures in the presence of PM. C, semi-preparative
chromatographic analysis of a sample at 6 days, monitoring absorbance
at 294 nm. The brackets in C indicate the region pooled from several
semi-preparative column runs and were used for mass spectrometry
analysis. The * indicates products produced during LA oxidation in the
absence of PM.

blocked lysine, was shown to be formed during copper-catalyzed oxidation of LDL, and was identified in the vascular wall
by immunohistochemical methods. Data on product 339 are
therefore presented in more detail here. Products 267 and 339
were isolated by semi-preparative RP-HPLC. Based on absorbance area units on HPLC, both products yielded PM (⬎90%) on
acid hydrolysis (2 N HCl, 2 h at 95 °C) (shown for product 339
in Fig. 9, A versus B). The fluorescence response of these
products on HPLC analysis was ⬃30% that of PM, consistent
with the loss of PM fluorescence during reaction of LA with PM
(Fig. 7, B versus A). Neither product contained a free amino

FIG. 8. Identification and kinetics of formation of pyridoxamine adducts in reactions of pyridoxamine with linoleic acid. A,
products formed after 6 days of reaction and eluting between 19 and 22
min (Fig. 7D) were analyzed by direct injection ESI-MS. Five major
products were identified, with m/z ⫽ 267, 305, 323, 339, and 479. B,
semi-preparative RP-HPLC (absorbance detection), identifying major
products with m/z ⫽ 339, 267, and 305, in order of elution. C, kinetics
of formation of 267 (●), 339 (f), and 305 (Œ), based on their area ratios
to pyridoxal, added as internal standard. The data shown are the mean
and S.D. from three independent experiments.

group, based on lack of reactivity with TNBS, consistent with
the loss of TNBS reactivity during lipid peroxidation reactions
(Fig. 1B).
The hexanoic acid amide and nonanedioic acid monoamide
derivative of PM were prepared synthetically, as described
under “Materials and Methods.” Analysis of the synthetic products by RP-HPLC-ESI-MS confirmed that they co-eluted with
products 267 and 339 obtained from the reaction mixture and
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FIG. 6. Pyridoxamine does not prevent copper-catalyzed oxidation of LDL but does inhibit ALE formation and lysine loss. LDL (50
g/ml) was incubated at 37 °C in phosphate-buffered saline alone (䡺) or in the presence of 5 M Cu2⫹ (●) or with 5 M Cu2⫹ and 100 M (⌬) or 250
M (Œ) PM. A, conjugated diene formation was monitored at 234 nm. At the end of the incubation ⬃1 mg of protein was removed, reduced with
NaBH4, dialyzed, delipidated, and then analyzed for CML, CEL, MDA-Lys, and HNE-Lys content by selected ion monitoring (SIM)-GC/MS (B) and
lysine loss (C) by amino acid analysis. Results are mean and range for analysis of two independent pools of LDL and are representative of two
separate experiments.
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yielded identical molecular ions by ESI-MS analysis. Acid hydrolysis (2 M HCl, 2 h, 95 °C) of products 267 and 339 (both
synthetic and from reaction mixtures) also yielded PM by
HPLC and either hexanoic or nonanedioic acid by GC/MS as
the propyl or dimethyl ester, respectively (shown for reaction
product 339 in Fig. 9, C and D). Both PM and the respective
carboxylic acid were formed in approximately equal proportions (⬎90% yield), confirming the identity of products 267 and
339.
Product 305 has not yet been isolated in sufficient amounts
for complete characterization. Based on its molecular formula,
determined by high resolution fast atom bombardment-MS,
product 305 is a 9-carbon mono-oxygenated adduct to PM,
possibly an epoxy or hydroxy acid derivative of PM. It was not
formed by reaction of HNE with PM in phosphate buffer (data
not shown). Product 479 was a minor reaction product. Its
molecular weight indicates that it is formed by adduction of PM
to an intact, dioxo-derivative of LA. Further characterization of
these and other reaction products is in progress.
DISCUSSION

PM Inhibition of Advanced Lipoxidation Reactions—PM was
originally described as an AGE inhibitor and, like other AGE
inhibitors, is thought to act as a nucleophilic trap for reactive
carbonyl intermediates in AGE formation. Reactive carbonyl
compounds are also involved in the formation of ALEs, so it
seemed likely that this compound would also inhibit chemical
modification of proteins during lipid peroxidation reactions.
Indeed, PM was a potent inhibitor of chemical modification of
both RNase and LDL during lipid peroxidation reactions, inhibiting both the modification of lysine residues and the formation of specific lipoxidation products, CML, CEL, MDA-Lys,
and HNE-Lys. Some weak antioxidant activity, a general characteristic of phenolic compounds, was also observed, as judged
by a marginal effect of PM on the kinetics of oxidation of

linoleate and LDL. However, the gradual solubilization of the
PUFA and chemical modification of PM in reactions in either
the absence or presence of protein, the formation of TBARS and
decomposition of LA (Fig. 2), as well as the formation of conjugated dienes during oxidation of LDL (Fig. 6) document that
lipid peroxidation occurred, even in the presence of PM. The
overall observations were consistent with the hypothesis that
PM acts as a sacrificial nucleophile, trapping reactive intermediates in lipoxidation (and glycoxidation) reactions. The involvement of the amino group of PM in inhibition of ALE
formation was confirmed by the loss of TNBS reactivity in
reactions of PM with oxidizing PUFA (Fig. 1B).
The fact that PM protects against modification of lysine
residues and formation of lipoxidation products in RNase, despite the 100-fold excess of PUFA and the 10-fold higher concentration of lysine residues on RNase (Figs. 3 and 4), illustrates its efficiency in trapping reactive carbonyl
intermediates. The efficiency of PM in protecting lysine amino
groups suggests either that only a fraction of lipid peroxidation
products participate in chemical modification of protein or that
PM intercepts critical, early lipid peroxidation products, preventing their decomposition to a broader range of shorter
-chain reactive carbonyl compounds. Consistent with the latter
hypothesis, none of the anticipated ALE derivatives of PM, e.g.
carboxymethyl-PM, carboxyethyl-PM, MDA-PM, or HNE-PM,
were identifiable in the PM ⫹ AA reaction mixture, based on
scanning for their molecular weight by LC-ESI-MS. Thus, it
appears that, by trapping early intermediates in glycoxidation
and lipoxidation reactions, PM protects against the formation
of a range of later precursors of ALEs on proteins.
The inhibition of lipoxidation in the RNase model system
suggested that PM would exert similar effects during coppercatalyzed oxidation of LDL. As shown in Fig. 6, despite the high
rate of lipoprotein oxidation catalyzed by 5 M Cu2⫹ in this
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FIG. 9. Characterization of reaction
product 339, the nonanedioic acid
monoamide derivative of PM. A, RPHPLC of product 339, isolated by semipreparative RP-HPLC. B, RP-HPLC of
product 339, following acid hydrolysis,
yielding PM in ⬎90% yield. C, GC/MS
analysis of the organic phase following
extraction and derivatization as the
methyl ester. NDA, nonanedioic acid dimethyl ester; PA, palmitic acid methyl
ester (derived from the internal standard,
palmitic acid). D, mass spectrum of the
product identified as NDA in C. Mass assignments: m/z 216 ⫽ molecular ion (not
detected); m/z 185 ⫽ M ⫺ CH3O; base
peak, m/z 152 ⫽ M ⫺ 2(CH3OH); m/z
143 ⫽ M ⫺ CH2COOCH3; m/z 125 ⫽ M ⫺
(COCH3 ⫹ CH3OH); m/z 111 ⫽ M ⫺
(CH2COOCH3 ⫹ CH3OH); m/z 97 ⫽ M ⫺
(CH2CH2COOCH3 ⫹ CH3OH); m/z 83 ⫽
M ⫺ (CH2CH2CH2COOCH3).
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reaction system, PM, at a pharmacologically relevant concentration, was an effective inhibitor of chemical modification of
LDL, including both the formation of specific ALEs and the
modification of lysine residues. These inhibitory effects, coupled with the lipid lowering activity of PM in diabetic rats,3
suggest that PM may be effective in protecting against lipiddependent, oxidative chemical modification of proteins in vivo
and may, therefore, have anti-atherogenic activity. Experiments to assess the effects of PM on formation of lipoxidation
products in vivo and development of diabetic vascular disease
are currently under way.
Mechanism of Action of PM—PM is unique among current
inhibitors of advanced glycation reactions because of its characteristic fluorescence spectrum. Thus, the carbonyl intermediates trapped by PM are not only amenable to RP-HPLC
analysis but are also readily identifiable by fluorescence detection (Fig. 7). These features of PM, combined with previous
work of Kato et al. (25, 26), facilitated the identification of the
hexanoic acid amide and nonanedioic acid monoamide derivatives of PM. These compounds are clearly formed by adduction
of PM to the 9- and 13-carbons of LA, followed by oxidative
cleavage of the 9 –10 or 12–13 carbon-carbon bonds (Scheme I).
We propose that carbonyl species, such as 9- and 13-oxo-octadecadienoic acids (keto-octadecadienoic acids; 9- and 13KODE) (27), formed from the lipid peroxides (hydroperoxyoctadecadienoic acids) are involved as intermediates in the reaction
mechanism. The reaction pathway proposed in Scheme I involves the formation of a carbinolamine adduct of PM to the
KODE, followed by metal-catalyzed, oxidative cleavage of the
carbon-carbon bond adjacent to a carbonyl group, yielding the
hexanoic amide from 13-KODE and nonanedioic acid monoamide from 9-KODE. Theoretically, bond cleavage could occur on
either side of the C-9- or C-13 carbonyl group, yielding the
alternative 10-carbon and 13-carbon amide derivatives of PM;
however, products with these molecular weights were not detectable by RP-HPLC-ESI-MS. Thus, the mechanism of formation of the hexanoic and nonanedioic acid adducts must account
for selective cleavage of the PM-LA intermediate on the conjugated, unsaturated side of the alkane chain. We propose that

this preferred cleavage is driven by stabilization of an intermediate radical released from the conjugated side of the hydrocarbon system during the cleavage reaction.
In support of this mechanism, KODEs have been identified
as products of both non-enzymatic (27, 28) and enzymatic (29,
30) peroxidation of LA and have also been detected by chemical
methods in atherosclerotic plaque (31). Thiol compounds are
known to react directly with KODEs, whereas their reaction
with hydroperoxyoctadecadienoic acids requires autoxidizing
conditions (Fe3⫹ and O2) (16, 17). PM also fails to react with
lipid peroxides (prepared from LA using soybean lipoxygenase)
under anti-oxidative conditions (anaerobic incubation in the
presence of DTPA; data not shown.). Thus, PM may function as
a surrogate, non-thiol nucleophile, trapping and inactivating
KODE intermediates and thereby inhibiting further chemical
modification of proteins by peroxidizing lipids.
Concluding Remarks—Based on the proposed mechanism of
formation of PM adducts, the hexamide derivative of lysine is
likely to be formed from any -6 PUFA. A number of other
mono- and dicarboxylic acid amide derivatives should also be
formed on oxidation of other families of PUFA. Analysis of the
amide content of tissue proteins should therefore provide insight into both the origin of lipid-derived chemical modifications of proteins and their contribution to the overall chemical
modification of proteins in vivo. These non-enzymatic lipid
adducts to protein promote protein-membrane interactions, affecting the endocytosis, subcellular transport, compartmentation, and catabolism of lipoxidized proteins. These and other
lipid adducts may also contribute to the accumulation of lipofuscin in postmitotic tissues during aging and to the accumulation of lipids and lipoproteins in foam cells in the vascular
wall in atherosclerosis. We are encouraged by the possibility
that inhibition of lipoxidative modification of proteins, using
compounds such as PM, may provide a route for limiting agedependent and disease-related damage to proteins by both
glycoxidation and lipoxidation reactions and may be useful for
treatment of diseases involving hyperlipidemia and/or oxidative stress.
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